Hindustan Unilever. Institutional Equities. 2QFY19 Result Update

Similar documents
Colgate-Palmolive (India)

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Gillette India. Institutional Equities. 1QFY18 Result Update

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

Hindustan Unilever. Institutional Equities. 1QFY19 Result Update

Nestle India. Institutional Equities. 1QCY18 Result Update. Resurgence Continues BUY. Sector: FMCG CMP: Rs8,981 Target Price: Rs10,700 Upside: 19%

Hindustan Unilever. Institutional Equities. 4QFY18 Result Update

Institutional Equities

Jamna Auto Industries

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Sanofi India. Institutional Equities. 3QCY18 Result Update. Robust Performance BUY

Indian Oil Corporation

Dalmia Bharat Enterprises

NESCO. Institutional Equities. Event Update. Revenues From Bombay Exhibition Centre May Take A Hit BUY

Dabur India. Institutional Equities. 1QFY19 Result Update

Dabur India. Institutional Equities. 4QFY18 Result Update. Growth Volatility Is Still Fairly High ACCUMULATE

Mold-Tek Packaging. Institutional Equities. Conference Update. Promising Growth Outlook BUY

EBITDA 5,076 3, , EBITDA

Hindustan Unilever. Institutional Equities. 3QFY18 Result Update BUY

Punjab National Bank

Institutional Equities

Thermax. Institutional Equities. 3QFY18 Result Update. Healthy Execution, But Margins Disappoint SELL

26 October 2018 Reuters: MRTI.BO; Bloomberg: MSIL IN

Indian Oil Corporation

Bata India. Institutional Equities. 1QFY19 Result Update BUY

South Indian Bank. Institutional Equities. 4QFY18 Result Update. Asset Quality Pain To Ease Hereafter BUY. 15 May 2018

Punjab National Bank

Swaraj Engines. Institutional Equities. 2QFY18 Result Update ACCUMULATE

Voltas. Institutional Equities. 1QFY19 Result Update. EMPS Shines, UCP Proves Its Mettle Again ACCUMULATE

Power Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy

Institutional Equities

Eicher Motors. Institutional Equities. Management Meet Update BUY. Reuters: EICH.NS; Bloomberg: EIM IN

Hindustan Unilever. Institutional Equities. Company Update. Faster And Stronger BUY. Sector: FMCG CMP: Rs1,350 Target Price: Rs1,570 Upside: 16%

Institutional Equities

Crisil. Institutional Equities. 3QCY17 Result Update ACCUMULATE. Weak SME Rating Revenues & Currency Movement Play Spoilsport

Institutional Equities

EBITDA 6,223 6,511 (4.4) 5, EBITDA

Institutional Equities

Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Institutional Equities

Mangalam Cement. Institutional Equities. 3QFY18 Result Update. Higher Operating costs Hurt Performance BUY

CARE Ratings. Institutional Equities. 2QFY18 Result Update BUY

Institutional Equities

Bajaj Electricals. Institutional Equities. 3QFY15 Result Update

TVS Motor Company. Institutional Equities. 3QFY19 Result Update SELL

Timken India. Institutional Equities. 4QFY16 Result Update BUY. Margin Expansion Leads To Huge Growth In Profit; Retain Buy

Institutional Equities

Institutional Equities

Crompton Greaves. Institutional Equities. 4QFY15 Result Update ACCUMULATE. Overseas Losses Continue; More Business Exits Likely

EBITDA 2,503 2,904 (13.8) 2,722 (8.0) EBITDA

Karnataka Bank. Institutional Equities. 4QFY18 Result Update. Plucky Bank And Low Hanging Fruit BUY. 17 May Reuters: KBNK.NS; Bloomberg: KBL IN

PNB Housing Finance. Institutional Equities. 4QFY18 Result Update BUY. Continued Display of Embedded Scalability. 4 May 2018

The Ramco Cements. Institutional Equities. Event Update BUY

Institutional Equities

Institutional Equities

2,09,057 1,85,859 2,17, (4.1) NIM

Sequent Scientific. Institutional Equities. 1QFY19 Result Update BUY

3,746 2,551 3, NIM

IFB Industries. Institutional Equities. 3QFY18 Result Update. Healthy Revenues, Strong Gross Margin; Retain Buy BUY.

Initiating Coverage. Uflex Ltd.

93,707 77,814 90, NIM

La Opala RG. Institutional Equities. 4QFY17 Result Update UNDER REVIEW. Revenues Soar, But Margins Take A Hit. Sector: Tableware CMP: Rs536

E&P To Stay Strong; Consumer Segment To Revive

ACC. Institutional Equities. Event Update. Capacity Expansion To Consolidate Presence In Central India ACCUMULATE

Manappuram Finance. Institutional Equities. 3QFY18 Result Update. The Glitter Is Back In Gold Loans BUY. 9 February 2018

Muthoot Finance. Institutional Equities. 2QFY18 Result Update BUY

EBITDA 1,548 1,814 (14.7) 1,561 (0.8) EBITDA

Muthoot Finance. Institutional Equities. 3QFY18 Result Update. Funding Cost Decline Combines With Operating Leverage BUY.

Institutional Equities

Institutional Equities

Bharat Financial Inclusion

Bata India. Institutional Equities. Management Meet Update. On Right Track ACCUMULATE. Sector: Retail CMP: Rs692 Target Price: 696 Upside: 1%

Muthoot Finance. Institutional Equities. 1QFY18 Result Update. Gold Loan Business Continues To Glitter BUY. 10 August 2017

Dalmia Bharat Enterprises

Atul Auto. Institutional Equities. Management Meet Update ACCUMULATE. Sector: Automobile CMP: Rs445 Target Price: Rs489 Upside: 10% 23 August 2017

Cadila Healthcare. Institutional Equities. 3QFY15 Result Update UNDER REVIEW. Stable Performance. Sector: Pharmaceuticals CMP: Rs1,514

9,500 7,914 8, NIM

Muthoot Finance. Institutional Equities. 2QFY19 Result Update. Weak quarter not structural in any way BUY. 10 December 2018

18,948 15,784 18, NIM

Dalmia Bharat Enterprises

La Opala RG. Institutional Equities. 1QFY18 Result Update

Institutional Equities

Swiss Glascoat Equipments

EBITDA 1,585 1,917 (17.3) 1,673 (5.2) EBITDA

V-Guard Industries. Institutional Equities. Conference-call Update BUY. Sector: White Goods CMP: Rs914 Target Price: Rs1,109 Upside: 21%

PNB Housing Finance. Institutional Equities. 2QFY19 Result Update BUY. Relatively Soft Quarter Not Structural In Nature.

EBITDA 5,019 4,211 5, EBITDA

Institutional Equities

9,251 7,812 8, NIM

Punjab National Bank

Sun Pharmaceutical Industries

Voltas. Institutional Equities. Management Meet Update ACCUMULATE. Sector: Capital Goods CMP: Rs309 Target Price: Rs325 Upside: 5% 23 December 2016

Punjab National Bank

Operating expenses tracked lower than core total income growth as ABL displayed continued

9,807 8,007 9, NIM

State Bank of India. Institutional Equities. 3QFY19 Result Update BUY

Manappuram Finance. Institutional Equities. 3QFY17 Result Update BUY

Muthoot Finance. Institutional Equities. 1QFY19 Result Update

State Bank of India. Institutional Equities. 1QFY18 Result Update

Robust results, TLT margins improved profitability.

Transcription:

2QFY19 Result Update Institutional Equities Hindustan Unilever 15 October 2018 Reuters: HLL.BO; Bloomberg: HUVR IN Best Proxy In A VUCA World Hindustan Unilever s (HUVR) overall performance in 2QFY19 was broadly in line with our expectations. The company reported yet another quarter of strong volume-led growth. Top-line adjusted for fiscal incentive adjustment was in line with our expectations. Operating profit and net earnings grew 20% and 26% YoY, respectively. This was the fifth consecutive quarter of more than 20% growth in EBITDA for HUVR. Domestic consumer growth of 12% was well ahead of 9% market growth. Volume growth adjusted for base saw a 100bps improvement as compared to previous quarter despite challenges of long truckers strike and unprecedented floods in Kerala. The growth was broad-based wherein all the categories continued their double-digit growth, despite lack of a favourable base till the last quarter. We believe that this is a function of stable demand trend, rural growth surpassing urban growth, HUVR s own initiatives and its investment in market development activities and also consistent innovation well ahead of peers. HUVR s strong focus on cost optimization and moderate competitive intensity helped the company in boosting operating margins by 160bps YoY despite a 200bps QoQ expansion in material costs. A calibrated pricing approach and improved rural trends in our opinion should help HUVR in maintaining high single digit volume growth in 2HFY19 and FY20 despite a not so favourable base. Its constant thrust on innovation, savings programme and premiumisation would support margin expansion. Taking cognisance of the inflationary environment after the sharp rise in crude oil prices and depreciation of the INR, we have revised our estimates downwards. We believe that considering the improvement in organisational capabilities through investment in customer development and supply chain, HUVR s ability to outperform in this volatile, Uncertain, Complex and Ambiguous (VUCA) world remains strong. Therefore, we continue to retain our Buy rating on HUVR with a revised target price of Rs.1,900 (from Rs.2,025 earlier) indicating an upside of 21% from CMP. The revision in target price factors in rolling forward the valuation to September 2020E earnings, reduction in earnings estimates by 2%-5%(FY19E and FY20E) and revised target PE multiple of 50x (from 55x earlier) to reflect the increased macro risks. Broad-based growth: HUVR has again delivered a strong double-digit volume-led growth in 2QFY18. Domestic consumer growth of 12% was supported by a 10% growth in volume across categories. All the categories grew in double digits, despite lack of a favourable base till the last quarter. There were many new product launches/campaigns (see Exhibit 7) during the quarter across categories. Robust operating profit growth continues: Strong focus on cost savings and efficiency along with a healthy growth trajectory of premium portfolio helped HUVR to report robust operating earnings growth despite crude oil price-related pressure. We believe that its constant thrust on innovation, savings programme and premiumisation would continue to support margin expansion. Outlook and valuation: We believe that considering the improvement in organisational capabilities through investment in customer development and supply chain, HUVR s ability to outperform in this VUCA world remains strong and it will continue to trade at a premium valuation compared to peers. We have retained Buy rating, after revising our estimates and rolling forward the valuation to Sept 2020E earnings, with a revised target price of Rs1,900 and target PE of 50x, indicating an upside of 21%. BUY Sector: FMCG CMP: Rs1,570 Target Price: Rs1,900 Upside: 21% Vijay Chugh Research Analyst vijay.chugh@nirmalbang.com +91-22-6273 8064 Abhishek Navalgund Junior Research Analyst abhishek.navalgund@nirmalbang.com +91-22-6273 8013 Key Data Current Shares O/S (mn) 2,164.6 Mkt Cap (Rsbn/US$bn) 3,397.6/46.2 52 Wk H / L (Rs) 1,809/1,216 Daily Vol. (3M NSE Avg.) 1,697,505 Price Performance (%) 1 M 6 M 1 Yr Hindustan Unilever (3.5) 11.1 26.5 Nifty Index (7.9) 0.1 3.7 Source: Bloomberg Y/E March (Rsmn) 2QFY18 1QFY19 2QFY19 YoY (%) QoQ (%) 1HFY18 1HFY19 YoY (%) Net sales 83,090 94,870 92,340 11.1 (2.7) 1,68,380 1,87,210 11.2 COGS 39,290 43,640 44,350 12.9 1.6 80,130 87,990 9.8 Gross margin % 52.7 54.0 52.0 (70bps) (200bps) 52.4 53.0 60bps Employee costs 4,350 4,420 4,380 0.7 (0.9) 8,540 8,800 3.0 % of sales 5.2 4.7 4.7 (50bps) 10bps 5.1 4.7 (40bps) Advertising costs 10,230 11,530 11,060 8.1 (4.1) 19,280 22,590 17.2 % of sales 12.3 12.2 12.0 (30bps) (20bps) 11.5 12.1 60bps Other expenses 12,400 12,770 12,360 (0.3) (3.2) 24,950 25,130 0.7 % of sales 14.9 13.5 13.4 (150bps) (10bps) 14.8 13.4 (140bps) EBITDA 16,820 22,510 20,190 20.0 (10.3) 35,480 42,700 20.3 EBITDA margin % 20.2 23.7 21.9 160bps (190bps) 21.1 22.8 170bps Depreciation 1,150 1,270 1,300 13.0 2.4 2,290 2,570 12.2 EBIT 15,670 21,240 18,890 20.5 (11.1) 33,190 40,130 20.9 EBIT margin % 18.9 22.4 20.5 160bps (190bps) 19.7 21.4 170bps Interest expenses 60 70 70 16.7 0.0 120 140 16.7 Other income 2,040 1,350 3,050 49.5 125.9 3,170 4,400 38.8 Exceptional items 360 (590) (350) (197.2) (40.7) 230 (940) (508.7) PBT 18,010 21,930 21,520 19.5 (1.9) 36,470 43,450 19.1 Tax 5,250 6,640 6,270 19.4 (5.6) 10,880 12,910 18.7 Effective tax rate % 29 30 29 - (110bps) 30 30 (10bps) Adjusted PAT 12,400 15,880 15,600 25.8 (1.8) 25,360 31,480 24.1 Adj. PAT margin % 14.6 16.5 16.4 180bps (10bps) 14.8 16.4 160bps EPS 5.7 7.3 7.2 25.8 (1.8) 11.7 14.5 24.1

Exhibit 1: Financial summary Y/E March (Rsmn) FY17 FY18 FY19E FY20E FY21E Net sales 3,18,899 3,45,250 3,88,272 4,32,868 4,76,666 YoY growth (%) 2.7 8.3 12.5 11.5 10.1 EBITDA 60,470 72,760 88,001 1,03,615 1,20,533 EBITDA margin (%) 19.0 21.1 22.7 23.9 25.3 PAT 44,904 52,360 62,078 75,296 87,342 EPS 19.6 24.5 29.1 34.8 40.4 YoY change (%) 2.7 24.7 18.9 19.5 16.0 RoCE (%) 88.5 100.2 114.9 134.6 160.1 RoE (%) 70.3 77.2 86.1 103.3 122.0 P/E (x) 46.4 66.9 53.9 45.1 38.9 P/BV (x) 30.4 50.1 46.2 47.0 47.9 EV/EBITDA (x) 31.7 47.7 37.8 32.0 27.4 Exhibit 2: Our estimates versus actual performance Y/E (Rsmn) 2QFY18 1QFY19 2QFY19 YoY (%) QoQ (%) NBIE estimate Variation (%) Net sales 83,090 94,870 92,340 11.1 (2.7) 93,655 (1.4) EBITDA 16,820 22,510 20,190 20.0 (10.3) 19,668 2.7 EBITDA (%) 20.2 23.7 21.9 160bps (190bps) 21.0 90bps Adj PAT 12,400 15,880 15,600 25.8 (1.8) 13,883 12.4 Exhibit 3: Change in our estimates Y/E March Old estimates New estimates Change (%) (Rsmn) FY19E FY20E FY21E FY19E FY20E FY21E FY19E FY20E FY21E Net sales 3,91,074 4,45,840-3,88,272 4,32,868 4,76,666 (0.7) (2.9) N.A. EBITDA 89,719 1,09,853-88,001 1,03,615 1,20,533 (1.9) (5.7) N.A. EBITDA (%) 22.9 24.6-22.7 23.9 25.3 (0.2) (0.7) N.A. Net income 63,543 79,707-62,078 75,296 87,342 (2.3) (5.5) N.A. 2 Hindustan Unilever

Exhibit 4: Category-wise performance Segment-wise results 2QFY18 1QFY19 2QFY19 YoY (%) QoQ (%) 1HFY18 1HFY19 YoY (%) Segment-wise revenues (Rsmn) 83,030 94,870 92,340 11.2 (2.7) 1,75,160 1,87,210 6.9 - Home care 27,390 31,460 30,800 12.4 (2.1) 57,860 62,260 7.6 - Beauty & personal care 39,100 44,070 43,160 10.4 (2.1) 82,780 87,230 5.4 - Foods solutions business 15,040 17,850 17,040 13.3 (4.5) 31,340 34,890 11.3 Others 1,500 1,490 1,340 (10.7) (10.1) 3,180 2,830 (11.0) Sales proportion (%) - Home care 33.0 33.2 33.4 40bps 20bps 33.0 33.3 20bps - Beauty & personal care 47.1 46.5 46.7 (40bps) 30bps 47.3 46.6 (70bps) - Foods solutions business 18.1 18.8 18.5 30bps (40bps) 17.9 18.6 70bps Others 1.8 1.6 1.5 (40bps) (10bps) 1.8 1.5 (30bps) Segment-wise results (Rsmn) 15,560 20,960 18,970 21.9 (9.5) 33,730 39,930 18.4 - Home care 3,830 6,020 4,920 28.5 (18.3) 8,310 10,940 31.6 - Beauty & personal care 9,480 11,620 11,150 17.6 (4.0) 20,270 22,770 12.3 - Foods solutions business 2,310 3,340 2,880 24.7 (13.8) 5,270 6,220 18.0 Others (60) (20) 20 (133.3) (200) (120) - (100.0) EBIT margin (%) - Home care 14.0 19.1 16.0 200bps (320bps) 14.4 17.6 320bps - Beauty & personal care 24.2 26.4 25.8 160bps (50bps) 24.5 26.1 160bps - Foods solutions business 15.4 18.7 16.9 150bps (180bps) 16.8 17.8 100bps Others (4.0) (1.3) 1.5 550bps 280bps (3.8) 0.0 380bps EBIT composition (%) - Home care 24.6 28.7 25.9 130bps (280bps) 24.6 27.4 280bps - Beauty & personal care 60.9 55.4 58.8 (210bps) 330bps) 60.1 57.0 (310bps) - Foods solutions business 14.8 15.9 15.2 30bps (80bps) 15.6 15.6 - Others (0.4) (0.1) 0.1 50bps 20bps (0.4) - 40bps Note: The above numbers are reported numbers. Following the change in accounting treatment, numbers in 1HFY18 column are not comparable Exhibit 5: Comparable sales growth category-wise Segments (%) 2QFY18 3QFY18 4QFY18 1QFY19 2QFY19 Home care 13 20 21 20 13 Beauty & personal care 8 17 13 14 11 Refreshment 10 13 14 Foods 11 18 10 14 12 Total 10 17 16 16 11 3 Hindustan Unilever

Conference-call highlights HUVR reported 11% sales growth led by a strong volume growth of 10% in 1QFY19. The growth was broad-based as all categories grew in double digits. This was similar to the previous quarter. The management indicated that rural growth surpassed urban growth. Also, it stated that demand outlook is stable. We believe the improved rural trajectory will boost volume growth in the coming quarters. Exhibit 6: Rural growth inching ahead of urban markets Source: Company presentation, Nirmal Bang Institutional Equities Research Strong volume-driven growth in home care was sustained wherein the fabric wash category grew in double digits led by premiumisation and market develeopment. Household care category also witnessed a strong volume growth. Personal care category also reported robust growth. Personal wash category grew on the back of strong growth in the premium portfolio namely, Dove and Pears soaps and also HUVR launched Lifebuoy at Rs5 price point to step up penetration in select markets. All other personal product segments continued their strong growth momentum on the back of ongoing innovation and market development activities. Food solution portfolio growth was led by strong performance of beverage portfolio and new activations etc. Exhibit 7: New product launches/campaigns during the quarter Category Brand Description Home care Domex Pick up the brush campaign in south India. Beauty and personal care Lifebuoy Penetration step-up Rs5 access pack launched in select markets. Beauty and personal care Fair & Lovely Relaunch of Men s Fair & Lovely Beauty and personal care TRESemme Relaunch with superior fragrance and packaging. Beauty and personal care Lakme Exclusive make up range launch Kareena Kapoor Khan by Lakme Absolute Food solution business Adityaa Acquired Adityaa Milk Ice cream. Source: Company presentation, Nirmal Bang Institutional Equities Research Performance of the naturals portfolio tracked internal expectations and is set to grow 2.5x the company average growth rate. Performance of Lever Ayush range and Indu Lekha has been satisfactory. Ayush is tracking expectations in south India market. The management is committed to invest in Ayush brand which will further strengthen its presence in the naturals market in other regions. 4 Hindustan Unilever

Exhibit 8: Strong profile of naturals across categories Source: Company presentation, Nirmal Bang Institutional Equities Research Operating margin during the quarter was up 160bps YoY, despite input price-related pressure. Segmentwise, all the divisions reported margin improvement led by healthy growth trend, premiumisation and strong product initiatives of HUVR. The management indicated that considering the crude oil prices and overall depreciation in the currency, pricing will come into play in 2HFY19 to mitigate its impact. Also, we believe the overall strategy to re-image HUVR by investing on customer development and market development activities will support margin expansion. In the quarter gone by also, the speed and agility across the value chain has served well the company and that gives it an edge over peers, in our opinion. Exhibit 9: Speed and agility across the value chain Source: Company presentation, Nirmal Bang Institutional Equities Research The management indicated that HUVR witnessed competitive pressure easing during the quarter. Also, considering the cost pressure, other consumer companies are not investing enough on market development and advertising. This will help HUVR to build its market share further. Also, in modern trade, the competitive pressure it witnessed a year ago was much higher compared to the current scenario. Acquisition of Adityaa Milk Ice Cream was completed in the last week of September 2018 and hence its impact on the performance was negligible, but the management sounded extremely optimistic on ice cream and frozen dessert space. 5 Hindustan Unilever

Exhibit 10: Expansion of ice-cream portfolio Source: Company presentation, Nirmal Bang Institutional Equities Research There has been one change in the accounting treatment. Fiscal incentives received for the factories located in specific areas have been reported under other income as against other operating income in the past. This will lower the revenue and EBITDA numbers. Adjusted for that, the revenues were broadly in line with our expectation. HUVR has appointed Mr. Leo Puri as an independent director who has an experience in global firms like McKinsey and Co, A.T. Kearney etc. Also, the HUVR board has recommended an interim dividend of Rs9 per share as against Rs8 per share in the same period last year. 6 Hindustan Unilever

2QFY17 2QFY17 2QFY17 3QFY17 3QFY17 3QFY17 4QFY17 4QFY17 4QFY17 1QFY18 1QFY18 1QFY18 2QFY18 2QFY18 2QFY18 3QFY18 3QFY18 3QFY18 4QFY18 4QFY18 4QFY18 1QFY19 1QFY19 1QFY19 2QFY19 2QFY19 2QFY19 Oct-13 Dec-13 Feb-14 Apr-14 Jun-14 Aug-14 Oct-14 Dec-14 Feb-15 Apr-15 Jun-15 Aug-15 Oct-15 Dec-15 Feb-16 Apr-16 Jun-16 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Oct-17 Dec-17 Feb-18 Apr-18 Jun-18 Aug-18 Oct-18 2QFY17 2QFY17 3QFY17 3QFY17 Institutional Equities 4QFY17 4QFY17 1QFY18 1QFY18 2QFY18 2QFY18 3QFY18 3QFY18 4QFY18 4QFY18 1QFY19 1QFY19 2QFY19 2QFY19 Exhibit 11: Robust volume growth continues (%) 14 12.0 12 11.0 11.0 10 8 6 4.0 4.0 4 2 0.0 0 (1.0) (2) (4) (6) (4.0) 10.0 Exhibit 12: Improved top-line performance (reported) (Rsmn) (%) 100,000 10.8 11.2 14 11.5 11.1 90,000 12 80,000 70,000 10 60,000 6.4 8 4.9 1.4 5.9 50,000 6 40,000 (1.0) 4 30,000 20,000 2 10,000 0 - -2 Net Sales (Rs mn) Sales growth (%) Exhibit 13: Strong operating profit trend Exhibit14: Net income trending upwards (Rsmn) (%) 24,000 14.1 23.9 24.0 20.6 30 22,000 19.7 20.0 25 20,000 12.3 20 18,000 15 16,000 5.1-5.2 10 5 14,000 0 12,000 (5) 10,000 (10) (Rsmn) 27.8 (%) 16,000 25.8 26 15,000 22.5 14,000 16.5 19.6 21 13,000 16 9.3 12,000 11.5 11,000 6.8 6.2 11 10,000 6 EBITDA (Rs mn) EBITDA growth % PAT (Rs mn) PAT Growth % Exhibit 15: Improved margin profile (Rsmn) (%) 23.7 24 16.5 16.0 23 22.5 16 21.9 21.9 22 15.9 15.5 15 15.2 21 20.1 15 20.2 19.6 20 14.8 14.5 14.7 19 14.3 14 17.9 17.6 18 13.5 13.5 17 13.3 13 Exhibit 16: One-year forward P/E (x) 60 55 50 45 40 35 30 25 EBITDA margin % PAT margin % (RHS) 1 yr Fwd PE 5 yr Median PE +1 SD -1 SD 7 Hindustan Unilever

Financials (standalone) Exhibit 17: Income statement Y/E March (Rsmn) FY17 FY18 FY19E FY20E FY21E Net sales 3,18,899 3,45,250 3,88,272 4,32,868 4,76,666 % Growth 2.7 8.3 12.5 11.5 10.1 COGS 1,56,842 1,62,320 1,82,033 2,00,818 2,19,468 Staff costs 16,198 17,450 18,250 19,699 21,692 Advertising costs 34,693 41,050 47,290 52,474 55,537 Other expenses 50,697 51,670 52,699 56,262 59,435 Total expenses 2,58,429 2,72,490 3,00,271 3,29,253 3,56,133 EBITDA 60,470 72,760 88,001 1,03,615 1,20,533 % growth 5.2 20.3 20.9 17.7 16.3 EBITDA margin (%) 19.0 21.1 22.7 23.9 25.3 Other income 5,259 5,690 6,352 7,434 7,737 Interest costs 215 210 240 220 220 Depreciation 3,960 4,780 5,119 5,519 5,894 Profit before tax (before exceptional items) 61,554 73,460 88,994 1,05,310 1,22,156 Exceptional items 2,411 (620) (940) 0 0 Tax 19,060 20,480 25,976 30,013 34,814 PAT (before exceptional items) 42,494 52,980 63,018 75,296 87,342 PAT 44,904 52,360 62,078 75,296 87,342 PAT margin (%) 13.9 14.9 15.7 17.1 18.0 % Growth 8.6 16.6 18.6 21.3 16.0 Exhibit 19: Balance sheet Y/E March (Rsmn) FY17 FY18 FY19E FY20E FY21E Share capital 2,164 2,164 2,164 2,164 2,164 Reserves 62,740 68,590 71,321 70,136 68,760 Net worth 64,904 70,754 73,485 72,299 70,924 Total debt - - - - - Deferred tax liability (1,600) (2,550) (2,550) (2,550) (2,550) Total liabilities 73,894 82,584 85,690 86,198 86,487 Gross block 43,190 49,190 53,190 57,190 60,690 Depreciation 6,650 11,430 16,549 22,068 27,962 Net block 36,540 37,760 36,641 35,122 32,728 Capital work-in-progress 5,730 7,960 7,500 7,000 6,500 Investments 2,600 2,560 3,106 3,463 3,337 Inventories 23,620 23,590 28,277 27,842 32,286 Debtors 9,280 11,470 11,933 11,786 14,333 Cash 19,770 42,024 39,170 42,481 46,037 Loans & advances 3,580 4,100 4,659 5,194 4,290 Other current assets 5,790 5,760 5,824 5,627 5,720 Total current assets 93,654 1,11,394 1,18,207 1,26,695 1,41,276 Creditors 60,060 70,130 71,951 75,498 83,240 Other current liabilities & provisions 11,960 16,230 17,472 20,778 22,403 Total current liabilities 72,020 86,360 89,424 96,276 1,05,644 Net current assets 21,634 25,034 28,783 30,419 35,632 Total assets 73,894 82,584 85,690 86,198 86,487 Exhibit 18: Cash flow Y/E March (Rsmn) FY17 FY18 FY19E FY20E FY21E PAT 44,904 52,360 62,078 75,296 87,342 Depreciation 3,960 4,780 5,119 5,519 5,894 Other income (5,259) (5,690) (6,352) (7,434) (7,737) (Inc.)/dec. in working capital 7,600 12,210 (2,150) 7,630 2,284 Cash flow from operations 56,464 69,350 65,047 88,446 95,520 Capital expenditure (-) (13,230) (8,230) (3,540) (3,500) (3,000) Net cash after capex 43,234 61,120 61,507 84,946 92,520 Interest paid (-) - - - - - Dividends paid (-) (42,929) (51,446) (59,346) (76,482) (88,717) Inc./(dec.) in total borrowings - - - - - Inc./(dec.) in investments (9,990) 6,684 (4,999) (6,312) (3,816) Cash from financial activities (42,149) (48,606) (58,972) (74,788) (87,053) Others 1,400 - - - - Opening cash balance 30,120 19,770 42,024 39,170 42,481 Closing cash balance 19,770 42,024 39,170 42,481 46,037 Exhibit 20: Key ratios Y/E March FY17 FY18 FY19E FY20E FY21E Per share (Rs) EPS 19.6 24.5 29.1 34.8 40.4 Book value 30.0 32.7 34.0 33.4 32.8 DPS 16.6 20.0 23.0 29.6 34.3 Valuation (x) P/Sales 5.7 10.1 8.7 7.8 7.1 EV/sales 5.6 9.9 8.6 7.7 6.9 EV/EBITDA 31.7 47.7 37.8 32.0 27.4 P/E 46.4 66.9 53.9 45.1 38.9 P/BV 30.4 50.1 46.2 47.0 47.9 Return ratios (%) RoCE 88.5 100.2 114.9 134.6 160.1 RoE 70.3 77.2 86.1 103.3 122.0 Profitability ratios (%) Gross margin 50.8 53.0 53.1 53.6 54.0 EBITDA margin 19.0 21.1 22.7 23.9 25.3 EBIT margin 17.7 19.7 21.3 22.7 24.1 PAT margin 13.9 14.9 15.7 17.1 18.0 Liquidity ratios (x) Current ratio 1.3 1.3 1.3 1.3 1.3 Quick ratio 1.0 1.0 1.0 1.0 1.0 Solvency ratio (x) Debt to equity ratio - - - - - Turnover ratios Total asset turnover ratio (x) 2.4 2.1 2.2 2.4 2.5 Fixed asset turnover ratio (x) 8.2 7.7 8.8 10.3 12.2 Debtor days 11 11 11 10 10 Inventory days 57 53 52 51 50 Creditor days 128 129 132 134 132 8 Hindustan Unilever

Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Institutional Equities Rating track Date Rating Market price (Rs) Target price (Rs) 29 September 2017 Buy 1,170 1,425 26 October 2017 Buy 1,272 1,460 20 December 2017 Buy 1,350 1,570 18 January 2018 Buy 1,371 1,700 15 May 2018 Buy 1,503 1,750 17 July 2018 Buy 1,751 2,025 15 October 2018 Buy 1,570 1,900 Rating chart 1900 1800 1700 1600 1500 1400 1300 1200 1100 1000 900 800 Not Covered Covered 9 Hindustan Unilever

Disclaimer Stock Ratings Absolute Returns BUY > 15 ACCUMULATE -5 to15 SELL < -5 DISCLOSURES This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as NBEPL ) for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001436. NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments. NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets. NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1 or more in the subject company at the end of the month immediately preceding the date of publication of this research report. NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company. Analyst Certification: We, Vijay Chugh, the Independent Research Analyst and Abhishek Navalgund, Junior Research Analyst are the authors of this report, hereby certify that the views expressed in this research report accurately reflects our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s) principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations. 10 Hindustan Unilever

DISCLAIMER This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader. This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions. The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries. Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report. This report is jointly prepared by Independent Research Analyst, Mr. Vijay Chugh who is registered with SEBI as Research Analyst having registration no. INH000005209 and Mr. Abhishek Navalgund employed with NBEPL as Junior Research Analyst. As represented by Third Party Research Analyst, there is no material conflict of interest of him. We reviewed the third party research report for material fact and information before distribution of the same. Copyright of this document vests exclusively with NBEPL. Our reports are also available on www.nirmalbang.com Access all our reports on Bloomberg, Thomson Reuters and Factset. Team Details: Name Email Id Direct Line Rahul Arora CEO rahul.arora@nirmalbang.com - Girish Pai Head of Research girish.pai@nirmalbang.com +91 22 6273 8017 / 18 Dealing Ravi Jagtiani Dealing Desk ravi.jagtiani@nirmalbang.com +91 22 6273 8230, +91 22 6636 8833 Pradeep Kasat Dealing Desk pradeep.kasat@nirmalbang.com +91 22 6273 8100/8101, +91 22 6636 8831 Michael Pillai Dealing Desk michael.pillai@nirmalbang.com +91 22 6273 8102/8103, +91 22 6636 8830 Nirmal Bang Equities Pvt. Ltd. Correspondence Address B-2, 301/302, Marathon Innova, Nr. Peninsula Corporate Park, Lower Parel (W), Mumbai-400013. Board No. : 91 22 6273 8000/1; Fax. : 022 6273 8010 11 Hindustan Unilever